{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:00:32Z","timestamp":1783994432086,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>To examine current patterns of hypertension (HTN) treatment in the United States, including blood pressure (BP) control, prevalence of different antihypertensive agents, and variations in treatment associated with patient and physician characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We used data from the National Disease and Therapeutic Index (NDTI), a nationally representative physician survey produced by QuintilesIMS. We selected patients with a diagnosis of HTN and identified those prescribed antihypertensive therapies. We analyzed the type of antihypertensive agents prescribed. Extent of BP control, and associated patient and physician characteristics. We calculated 95% confidence intervals that accounted for the multistage NDTI sampling design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Among those treated for HTN in 2014, BP control varied: systolic BP (SBP) \u2265160 (15%) vs. SBP 150\u2013159 (9%) vs. SBP 140\u2013149 (19%) vs. SBP 130\u2013139 (26%) vs. SBP &lt;130 (32%). Of those treated for HTN, 29% used of angiotensin-converting enzyme inhibitors (ACEIs); 24%, thiazide-like diuretics; 22%, angiotensin receptor blockers (ARBs), 21%, calcium-channel blockers (CCBs); and 19% beta-blockers. Newer drugs had very limited uptake; no drugs approved after 2002 were used in more than 5% of patients. Selection of agents varied only modestly by patient and physician characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The treatment of HTN in 2014 predominantly involved older medications in 5 major classes of drugs: ACEIs, thiazide diuretics, ARBs, CCBs, and beta-blockers. Selection of antihypertensive agents showed limited variation by age, gender, race, and insurance type. Although 58% of treated patients had SBP &lt;140, 24% had poorly controlled HTN with SBP \u2265150, indicating the need for improved treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpx085","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T15:08:28Z","timestamp":1493478508000},"page":"1008-1014","source":"Crossref","is-referenced-by-count":75,"title":["Current Trends of Hypertension Treatment in the United States"],"prefix":"10.1093","volume":"30","author":[{"given":"Shreya J","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Medicine, Stanford University, Palo Alto, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall S","family":"Stafford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Palo Alto, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"2019120223310095300_CIT0001","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"2019120223310095300_CIT0002","volume-title":"Heart disease and stroke statistics: 2008 update at-a-glance","author":"Rosamond","year":"2008"},{"key":"2019120223310095300_CIT0003","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"2019120223310095300_CIT0004","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/CIRCULATIONAHA.114.010676","article-title":"Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals","volume":"130","author":"Egan","year":"2014","journal-title":"Circulation"},{"issue":"220","key":"2019120223310095300_CIT0005","first-page":"1","article-title":"Hypertension Prevalence and Control Among Adults: United States, 2011\u20132014","author":"Yoon","year":"2015","journal-title":"NCHS Data Brief"},{"key":"2019120223310095300_CIT0006","author":"Davis","year":"2013"},{"key":"2019120223310095300_CIT0007","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"2019120223310095300_CIT0008","first-page":"e28","article-title":"Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"2019120223310095300_CIT0009","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"2019120223310095300_CIT0010","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"2019120223310095300_CIT0011","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.114.04012","article-title":"Trends in blood pressure among adults with hypertension: United States, 2003 to 2012","volume":"65","author":"Yoon","year":"2015","journal-title":"Hypertension"},{"key":"2019120223310095300_CIT0012","first-page":"1692","article-title":"Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals","volume-title":"Circulation","author":"Egan","year":"2014"},{"key":"2019120223310095300_CIT0013","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"2019120223310095300_CIT0014","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/CIRCULATIONAHA.111.059303","article-title":"Hypertension and heart failure: the ALLHAT imperative","volume":"124","author":"Rodeheffer","year":"2011","journal-title":"Circulation"},{"key":"2019120223310095300_CIT0015","doi-asserted-by":"crossref","first-page":"e0119292","DOI":"10.1371\/journal.pone.0119292","article-title":"National trends in the ambulatory treatment of hypertension in the United States, 1997\u20132012","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS ONE"},{"key":"2019120223310095300_CIT0016","volume-title":"NDTI Diagnosis Reference File, 2000 to 2014","author":"IMS Health","year":"2000  2014"},{"key":"2019120223310095300_CIT0017","unstructured":"Zell\n              ER\n            \n            \n              McCaig\n              LF\n            \n            \n              Kupronis\n              BA\n            \n            \n              Besser\n              RE\n            \n            \n              Schuchat\n              A\n            \n          .\nA comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. Proceedings of the section on survey research methods, American Statistical Association. Alexandria, VA: American Statistical Association. 2000; 840\u2013845."},{"key":"2019120223310095300_CIT0018","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s11606-011-1796-4","article-title":"National trends in ambulatory asthma treatment, 1997\u20132009","volume":"26","author":"Stafford","year":"2011","journal-title":"J Gen Intern Med"},{"key":"2019120223310095300_CIT0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0735-1097(02)02670-0","article-title":"The underutilization of cardiac medications of proven benefit, 1990 to 2002","volume":"41","author":"Stafford","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2019120223310095300_CIT0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","article-title":"National trends in oral anticoagulant use in the United States, 2007 to 2011","volume":"5","author":"Kirley","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2019120223310095300_CIT0021","volume-title":"National Disease and Therapeutic Index","author":"IMS Health Incorporated","year":"2004"},{"key":"2019120223310095300_CIT0022","first-page":"5","article-title":"How to document and code for hypertensive diseases in ICD-10","volume":"21","author":"Beckman","year":"2014","journal-title":"Fam Pract Manag"},{"key":"2019120223310095300_CIT0023","author":"ICD-9-CM Official Guidelines for Coding and Reporting. Baltimore, MD: Centers for Medicare & Medicaid Services and National Center for Health Statistics","year":"2011"},{"key":"2019120223310095300_CIT0024","volume-title":"Age Differences in Visits to Office-Based Physicians by Adults With Hypertension: United States, 2013. NCHS Data Brief, No 263","author":"Ashman","year":"2016"},{"key":"2019120223310095300_CIT0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1370\/afm.1467","article-title":"Screening for hypertension annually compared with current practice","volume":"11","author":"Garrison","year":"2013","journal-title":"Ann Fam Med"},{"key":"2019120223310095300_CIT0026","author":"Drugs@FDA: FDA Approved Drug Products","year":"2016"},{"key":"2019120223310095300_CIT0027","volume-title":"U.S. Population Totals by Age Group and Sex in the 2010 and 2000 Censuses","author":"U.S Department of Health and Human Services\u2014Administration for Community Living","year":"2010"},{"key":"2019120223310095300_CIT0028","author":"US Census Bureau","year":"2011"},{"key":"2019120223310095300_CIT0029","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/HYPERTENSIONAHA.115.06851","article-title":"Patterns and correlates of baseline thiazide-type diuretic prescription in the Systolic Blood Pressure Intervention Trial","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/article-pdf\/30\/10\/1008\/31190762\/hpx085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajh\/article-pdf\/30\/10\/1008\/31190762\/hpx085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T23:31:53Z","timestamp":1575329513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/30\/10\/1008\/3844728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,5,22]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpx085","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,5,22]]}}}